Daratumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Daratumumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target CD38
Clinical data
Legal status
?
Identifiers
CAS number 945721-28-8 N
ATC code None
UNII 4Z63YK6E0E YesY
Chemical data
Formula C6466H9996N1724O2010S42 
 N (what is this?)  (verify)

Daratumumab is an investigational anti-cancer drug. It binds to CD38.[1] Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.[2]

Clinical trials[edit]

Encouraging preliminary results were reported in June 2012 from a Phase 1/2 clinical trial in relapsed multiple myeloma patients.[3] Updated trial results presented in December 2012 indicate daratumumab is continuing to show promising single-agent anti-myeloma activity.[4]

References[edit]

  1. ^ World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information 23 (2). 
  2. ^ "'Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab'". Janssen Biotech. Retrieved 2013-01-31. 
  3. ^ "ASCO: Drug Shows Promise in Myeloma". MedPage Today. 
  4. ^ "'Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)'". The Myeloma Beacon. Retrieved 2013-01-31.